You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?
ExpreS2ion Biotechnologies - Presentation of half-year 2025 report

You can already now sign up for the event and send in your questions. You don’t have to participate live to submit your questions for the event.
ExpreS2ion Biotechnologies is expected to release its Half-Year 2025 report on August 21, 2025. Later the same day at 10:30 CET, the management team will present the results and key achievements in a live online presentation. The presentation will be followed by a Q&A session.
In addition to the financial results, the focus could be on the capital situation and runway through 2025, as well as an update on the timelines for the ES2B-C001 candidate. This is especially relevant in light of the recent news regarding the first patient being dosed in the Phase 1 trial. Additionally, Austrian authorities have approved the company’s protocol amendment ahead of schedule, which expands the number of trial sites and allows testing in combination with other ADCs, potentially increasing the patient population. There could also be some focus on the recent positive news flow from the associated company AdaptVac.
ExpreS2ion Biotechnologies is a Danish pharmaceutical company focused on the development of vaccines through the use of its ExpreS2 production platform in combination with AdaptVac's VLP technology.
Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Digital IR/Corporate Visibility subscription agreement. /Michael Friis, 09.12 AM, 3 July 2025.